On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock!
The stock is now at a historic low: $3.31. In January 2021 it was $788.
Just to reach the Analyst Price Target, it need to grow 81.5X from this level. The Market cap is extremely low: 4.58 Mil. 81X would be $371 Mil. And wouldn`t be too much, if we look at their pipeline: 2 candidates reaching Phase 3 clinical trials, 3 candidates in Phase 2 and one in Phase one, in the following fields: Digestive/Nutritional Diseases, Inflammatory Diseases and Oncology. It can explode anytime.
Even though the institutional ownership it`s not high, some of the shareholders that recently reported increasing stakes in the company are: Goldman Sachs, Blackrock and Jane Street Group.
This one is a premium call in my opinion. Looking forward to read your opinion about it.
it was never 788$ there has been two splits . and today is the day you wanna enter if your long
reserved010
⋅
hi mate, is there any chance that you could revisit FWBI by any chance, I can see it has dropped to all time low at the moment but not sure what to expect next..? Will it go lower or we can expect some upside movements? and what would be the time scale for them please? Very much appreciated, Matt
alkuhawlik72
⋅
@reserved010, if your looking to get in we have reached a major support level today. 80 percent drop since he posted this
the stock just went for a split, I dont think it will rise that much...its not down..
TopgOptions
⋅
@coweed2020, it`s not down with a market cap of 4.5Mil?
alkuhawlik72
⋅
@coweed2020, you are correct after splits comes massive down falls but lowers the outstanding shares there for when its done with downtrend such as today. :quite possibly: its ten x times easier to pump. less shares wit higher market cap. seems like most companies start with a insane number of share so they have room to splt as they grow. News should start getting released now